Novo Nordisk held its first India Day in Bengaluru today, bringing company leadership together with local health and research partners to mark what it calls a long-term commitment to India's health and science future. The gathering reflects how GLP-1 makers are now planning years, not quarters, ahead. That same forward-looking mood carries through today's other developments, from stock forecasts to fresh research on how these drugs might help beyond diabetes and weight loss.
The Bengaluru event brought Novo's leadership together with researchers and public health partners from across India's science community. The company framed the day around research partnerships and sustainability commitments rather than any single product launch, the kind of institutional relationship that outlasts a single drug cycle. That framing matters for a market where Novo's GLP-1 medicines are still expanding access, since the company is signaling a lasting presence rather than a short-term distribution push. For a country with growing rates of diabetes and obesity, this kind of long-term positioning can affect how quickly new treatments and research reach patients.
Turning from strategy to stock price, a new financial forecast looks at what a $5,000 investment in Eli Lilly today might be worth by 2031, using the company's growth in GLP-1 medicines as the basis for its projection. Lilly's rise has been driven largely by demand for its diabetes and weight-loss drugs, and forecasts like this one are becoming more common as investors try to gauge how much room is left in the company's valuation. I would suggest reading these projections as one input among several, since they rest on assumptions about future sales that may or may not hold. Still, the fact that this kind of long-range forecast is being published says something about how central Lilly has become to conversations about the GLP-1 market's future.
That same growth story extends beyond diabetes and weight loss, as a new study points to a GLP-1 ingredient's potential to reduce asthma attacks and COPD flare-ups. Researchers found a link between the ingredient and fewer respiratory flare-ups in patients, adding to a growing body of evidence that GLP-1 drugs may have effects beyond their original indications. This kind of finding is still early, and a link identified in a study is not the same as a proven treatment effect, so I would suggest patients with asthma or COPD talk to their doctor before drawing conclusions about their own care. If the effect holds up in further research, it could change how these medications are used in respiratory disease.
The research pipeline is also producing new companies, not just new findings. Kura is spinning its diabetes research program into an independent biotech startup, with backing from Eli Lilly. This kind of arrangement lets a larger pharmaceutical company support early-stage science without absorbing it directly into its own operations, while the smaller team retains more control over its own direction. For Lilly, the move expands its involvement in diabetes research beyond its existing drug portfolio, and it reflects a broader pattern of large GLP-1 companies investing in adjacent science rather than developing everything in-house.
Not every voice in the market is bullish on Lilly's trajectory, though. Jim Cramer has said he prefers Johnson & Johnson over both Eli Lilly and Pfizer among healthcare stocks, a preference that runs against the enthusiasm reflected in some of today's other coverage. His view is a reminder that even with strong demand for GLP-1 drugs, not every analyst treats Lilly as the automatic top pick in the sector. Readers weighing their own positions may want to look at both sides of that argument rather than following either view on its own.
Taken together, today's stories point to a company thinking about its future in India and investors thinking about Lilly's future in the market, both looking well past the current quarter. If you hold Lilly stock or are considering it, it may be worth reading both the growth forecast and Cramer's more cautious take before deciding where you stand. If you or someone you know manages asthma or COPD, keep an eye on how the respiratory research develops, since early findings like this often take years to translate into actual treatment options. For now, the clearest signal is that GLP-1 companies are building for the long term, both in new markets like India and in the smaller ventures now spinning out of their research programs.
Key details
Novo's first India Day in Bengaluru signals lasting investment in health and science.
One financial forecast estimates what a $5,000 stake in Eli Lilly could grow to by 2031.
A new study suggests a GLP-1 ingredient may reduce asthma attacks and COPD flare-ups.
Kura is turning its diabetes research into a new biotech startup backed by Lilly.
Jim Cramer favors Johnson & Johnson over Eli Lilly and Pfizer among healthcare stocks.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.